Contineum CSO trades 8,124 CTNM shares in plan

Contineum Therapeutics’ Chief Scientific Officer Daniel S. Lorrain exercised stock options and sold shares in pre-planned trades.

Rhea-AI Filing Summary

Contineum Therapeutics’ Chief Scientific Officer Daniel S. Lorrain exercised stock options and sold shares in pre-planned trades. He exercised options covering 8,124 shares of Class A common stock at an exercise price of $1.01 per share, then sold 8,124 shares in open-market transactions at weighted average prices around $16 per share under a Rule 10b5-1 trading plan adopted on September 23, 2025. After these transactions, he directly owned 156,052 shares of Class A common stock, with an additional 6,842 shares held indirectly by his spouse.

Insider Trade Summary

Exercise and Sale: 8,124 shares ($122K approx. pre-tax spread)

Exercise and Sale 7 txns

Insider Lorrain Daniel S.

Role Chief Scientific Officer

Sold 8,124 shs ($130K)

Approx. gross sale proceeds $130K

Approx. exercise cost $8K

Approx. pre-tax spread $122K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	3,824	$0.00	$0.00
Exercise	Class A Common Stock	3,824	$1.01	$4K
Sale	Class A Common Stock	3,824	$16.0115	$61K
Exercise	Stock Option (right to buy)	4,300	$0.00	$0.00
Exercise	Class A Common Stock	4,300	$1.01	$4K
Sale	Class A Common Stock	4,300	$16.0316	$69K
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 67,306 contracts (Direct); Class A Common Stock — 156,052 shares (Direct); Class A Common Stock — 6,842 shares (Indirect, By Spouse)

Footnotes (4)

1. F1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.15, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.05, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
4. F4. The stock options are fully vested and exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Contineum Therapeutics (CTNM) insider Daniel S. Lorrain report on this Form 4?

Daniel S. Lorrain reported exercising stock options and selling shares of Contineum Therapeutics (CTNM) common stock. He exercised options for 8,124 shares at $1.01 per share and sold 8,124 shares in open-market transactions at weighted average prices near $16 per share.

How many Contineum Therapeutics (CTNM) shares did Daniel S. Lorrain sell?

Daniel S. Lorrain sold a total of 8,124 shares of Contineum Therapeutics Class A common stock. The sales occurred in two blocks of 4,300 and 3,824 shares at weighted average prices of about $16.03 and $16.01 per share, respectively.

Were Daniel S. Lorrain’s CTNM stock sales under a 10b5-1 trading plan?

Yes. The filing states these transactions were effected under a Rule 10b5-1 trading plan adopted on September 23, 2025. Such plans allow insiders to pre-schedule trades, helping separate personal trading decisions from later nonpublic company information.

What is Daniel S. Lorrain’s Contineum Therapeutics (CTNM) share ownership after these transactions?

After the reported transactions, Daniel S. Lorrain directly owned 156,052 shares of Contineum Therapeutics Class A common stock. The filing also shows an additional 6,842 shares held indirectly, reported as owned by his spouse.

What stock options did Daniel S. Lorrain exercise in Contineum Therapeutics (CTNM)?

Daniel S. Lorrain exercised fully vested stock options covering 4,300 and 3,824 shares of Contineum Therapeutics Class A common stock. The options had an exercise price of $1.01 per share, and the underlying options were reported as fully vested and exercisable.

At what prices were Daniel S. Lorrain’s CTNM shares sold?

The filing reports weighted average sale prices of $16.0316 and $16.0115 per share. Footnotes explain that actual sale prices ranged from $16.00 to $16.15 and from $16.00 to $16.05, respectively, across multiple individual trades.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 04:39 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lorrain Daniel S.

(Last) (First) (Middle)

3565 GENERAL ATOMICS COURT, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/24/2026		M(1)		4,300	A	$1.01	160,352	D
Class A Common Stock	02/24/2026		S(1)		4,300	D	$16.0316(2)	156,052	D
Class A Common Stock	02/25/2026		M(1)		3,824	A	$1.01	159,876	D
Class A Common Stock	02/25/2026		S(1)		3,824	D	$16.0115(3)	156,052	D
Class A Common Stock								6,842	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.01	02/24/2026		M(1)			4,300	(4)	02/24/2030	Class A Common Stock	4,300	$0	71,130	D
Stock Option (right to buy)	$1.01	02/25/2026		M(1)			3,824	(4)	02/24/2030	Class A Common Stock	3,824	$0	67,306	D

Explanation of Responses:

1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.15, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.05, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

4. The stock options are fully vested and exercisable.

	/s/ Peter Slover, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.